2/9/2016
`
`Xeljanz - FiercePharmaMarketing
`
`FiercePharmaMarketing
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Pharma Marketing News Brief
`Want to get the latest stories on business strategy, consumer advertising, new drug launches and more sent straight to your inbox? Join your fellow
`pharma marketing executives who subscribe to FiercePharmaMarketing for FREE!
`
`Click here for a sample.
`
`We never sell or give away your contact information. Our readers trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES JOBS
`
`FOLLOW US
`
`J O I N 2 4 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharmaMarketing is the leading source of
`pharma marketing news with a special focus on
`consumer advertising, DTC trends, new drug
`launches, and more. Join your fellow pharma
`marketing executives who get
`FiercePharmaMarketing via email. Sign up today!
`
`EMAIL ADDRESS
`
`Xeljanz
`The top 10 most-advertised prescription drug brands
`
`SHARE
`
`Total: $160.7 million
`
`Pfizer's ($PFE) rheumatoid arthritis drug Xe janz has been
`gaining steam since its launch in 2012, both in ad spending
`and in sales. Pfizer spent more than $160 million last year
`to advertise Xeljanz, up 69% from $94.9 million in 2013.
`Sales leaps were even higher, with Pfizer recording a
`revenue increase of 170% year over year to $308 million for
`the drug. Still, Xe janz has been another slow-to-grow drug
`for Pfizer, which had once pegged peak sales expectations
`at $3 billion annually.
`
`Xeljanz was accepted earlier this year for FDA review for
`the treatment of adult psoriasis, an indication that could
`boost sales, although it's entering an already crowded field
`where blockbuster Humira is well entrenched.
`
`For more:
`Psoriasis data wars heat up at AAD with Novartis, Boehringer studies
`Psoriasis study does little to help Pfizer with Xeljanz
`Pfizer's potential stars Eliquis, Xeljanz see sluggish sales
`
`TOOLS
`
`Comment
`
`Print
`
`Special Report: The top 10 most-advertised prescription drug brands
`
`MOST READ MOST SHARED
`
`POPULAR STORIES
`
`1
`
`2
`
`3
`
`4
`
`5
`
`Cialis
`
`Lyrica
`
`Eliquis
`
`Viagra
`
`Humira
`
`6
`
`7
`
`8
`
`9
`
`Latuda
`
`Xeljanz
`
`Celebrex
`
`Abilify
`
`10 Chantix
`
`BACK
`
`STORY HOME
`
`NEXT
`
`Valeant, AstraZeneca played the Super Bowl ad
`game, but did they win?
`'Safe' social network LinkedIn emerges as popular
`marketing tool for pharma
`Pfizer keeps pushing on early hit Ibrance as
`Novartis, Lilly rivals near market
`GSK's slow-off-the-blocks Anoro gets a leg up from
`Incruse sidekick
`Docs take aim at Novartis' 'horrifying' Entresto ad
`
`THE LIBRARY: WEBINAR
`Special Considerations for Managing Immuno-
`oncology Studies - A New Paradigm
`
`| MARCH 9 | 11AM ET / 8AM PT |
`PRESENTED BY: MEDPACE
`
`http://www.fiercepharmamarketing.com/special-reports/top-10-most-advertised-prescription-drug-brands-xeljanz
`
`1/3
`
`Page 1 of 2
`
`SENJU EXHIBIT 2299
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`Xeljanz - FiercePharmaMarketing
`
`FiercePharmaMarketing
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Pharma Marketing News Brief
`Want to get the latest stories on business strategy, consumer advertising, new drug launches and more sent straight to your inbox? Join your fellow
`pharma marketing executives who subscribe to FiercePharmaMarketing for FREE!
`
`Click here for a sample.
`
`We never sell or give away your contact information. Our readers trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES JOBS
`
`FOLLOW US
`
`J O I N 2 4 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharmaMarketing is the leading source of
`pharma marketing news with a special focus on
`consumer advertising, DTC trends, new drug
`launches, and more. Join your fellow pharma
`marketing executives who get
`FiercePharmaMarketing via email. Sign up today!
`
`EMAIL ADDRESS
`
`Xeljanz
`The top 10 most-advertised prescription drug brands
`
`SHARE
`
`Total: $160.7 million
`
`Pfizer's ($PFE) rheumatoid arthritis drug Xe janz has been
`gaining steam since its launch in 2012, both in ad spending
`and in sales. Pfizer spent more than $160 million last year
`to advertise Xeljanz, up 69% from $94.9 million in 2013.
`Sales leaps were even higher, with Pfizer recording a
`revenue increase of 170% year over year to $308 million for
`the drug. Still, Xe janz has been another slow-to-grow drug
`for Pfizer, which had once pegged peak sales expectations
`at $3 billion annually.
`
`Xeljanz was accepted earlier this year for FDA review for
`the treatment of adult psoriasis, an indication that could
`boost sales, although it's entering an already crowded field
`where blockbuster Humira is well entrenched.
`
`For more:
`Psoriasis data wars heat up at AAD with Novartis, Boehringer studies
`Psoriasis study does little to help Pfizer with Xeljanz
`Pfizer's potential stars Eliquis, Xeljanz see sluggish sales
`
`TOOLS
`
`Comment
`
`
`Special Report: The top 10 most-advertised prescription drug brands
`
`MOST READ MOST SHARED
`
`POPULAR STORIES
`
`1
`
`2
`
`3
`
`4
`
`5
`
`Cialis
`
`Lyrica
`
`Eliquis
`
`Viagra
`
`Humira
`
`6
`
`7
`
`8
`
`9
`
`Latuda
`
`Xeljanz
`
`Celebrex
`
`Abilify
`
`10 Chantix
`
`BACK
`
`STORY HOME
`
`NEXT
`
`Valeant, AstraZeneca played the Super Bowl ad
`game, but did they win?
`'Safe' social network LinkedIn emerges as popular
`marketing tool for pharma
`Pfizer keeps pushing on early hit Ibrance as
`Novartis, Lilly rivals near market
`GSK's slow-off-the-blocks Anoro gets a leg up from
`Incruse sidekick
`Docs take aim at Novartis' 'horrifying' Entresto ad
`
`THE LIBRARY: WEBINAR
`Special Considerations for Managing Immuno-
`oncology Studies - A New Paradigm
`
`| MARCH 9 | 11AM ET / 8AM PT |
`PRESENTED BY: MEDPACE
`
`http://www.fiercepharmamarketing.com/special-reports/top-10-most-advertised-prescription-drug-brands-xeljanz
`
`1/3
`
`Page 1 of 2
`
`SENJU EXHIBIT 2299
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`2/9/2016
`
`Xeljanz - FiercePharmaMarketing
`
`Immuno-Oncology Webinar: We are in a new
`era for researching cancer treatments. Join
`Medpace medical and operations experts as
`they discuss the unique considerations for
`managing immuno-oncology studies as well as
`insights into best practices. Register now!
`
`MORE ITEMS
`
`LATEST COMMENTARY
`
`Pharma marketers steer through changing tides
`What caught our readers' fancy this year? Here's
`your top 10 FiercePharmaMarketing capsule
`Merck KGaA exits 'sea of sameness' with futuristic
`rebrand
`For sale: Orange paint. It might just become your
`brand's signature
`FiercePharmaMarketing will now publish every
`Monday and Wednesday
`
`EVENTS
`Brand New Modular Bioprocessing Facility
`From Novartis
`February 17, 2016 — Charleston, SC
`MORE EVENTS
`
`
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`A publication of
`
`FiercePharmaMarketing is
`the leading source of
`pharma marketing news with
`a special focus on
`consumer advertising,
`DTC trends, new drug
`launches, and more. Join
`your fellow pharma
`marketing executives who
`get FiercePharmaMarketing
`via email for their must
`know news.
`
`Click here to get your free
`email briefing today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`FierceInstaller
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`FierceCities
`FierceGovHealthIT
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaAsia
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceDevOps
`FierceEnterpriseCommunicatio
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`SmartGridNews
`FierceWater
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscr be Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2016 FierceMarkets, a division of Questex, LLC. All rights reserved.
`
`http://www.fiercepharmamarketing.com/special-reports/top-10-most-advertised-prescription-drug-brands-xeljanz
`
`2/3
`
`Page 2 of 2
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
